-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s Solbinsiran Sodium
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s LY-3819469
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Eli Lilly and Co's LY-3819469 Drug Details: LY-3819469 (DCR-CM2) is under development for the treatment of atherosclerotic cardiovascular disease (ASCVD). The drug candidate is...
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s Mevidalen Hydroxybenzoate
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s PR-001
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s Imlunestrant tosylate
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s LY-3556050
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eli Lilly and Co’s Insulin efsitora alfa
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Solid Tumor Drug Details: ELI-002 (VED-002) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Colorectal Cancer Drug Details: ELI-002 (VED-002) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Solid Tumor Drug Details: ELI-002 (VED-002) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Pancreatic Ductal Adenocarcinoma Drug Details: ELI-002 (VED-002) is under development for the treatment...
-
Product Insights
![]()
Komsomolskoye (ELI) Field, Russia
Komsomolskoye (ELI) upstream field is located in Kalmykia Republic, Russia. The upstream field is owned by Komsomolskneft. It is operated by Komsomolskneft. The project started its operations in 2005. Komsomolskoye (ELI) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide proprietary forecasts of...
-
Product Insights
![]()
Sovkhoznoye (ELI) Field, Russia
Sovkhoznoye (ELI) upstream field is located in Kalmykia Republic, Russia. The upstream field is owned by Gazprom Gazoraspredeleniye Elista. It is operated by Gazprom Gazoraspredeleniye Elista. The project started its operations in 2005. Sovkhoznoye (ELI) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also...
-
Product Insights
![]()
Nadezhdinskoye (ELI) Field, Russia
Nadezhdinskoye (ELI) upstream field is located in Kalmykia Republic, Russia. The upstream field is owned by Evrosibneft. It is operated by Evrosibneft. The project started its operations in 2005. Nadezhdinskoye (ELI) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also provide proprietary forecasts of...
-
Product Insights
![]()
Komsomolskoye North (Severo-Komsomolskoye) (ELI) Field, Russia
Komsomolskoye North (Severo-Komsomolskoye) (ELI) upstream field is located in Kalmykia Republic, Russia. The upstream field is owned by Komsomolskneft. It is operated by Komsomolskneft. The project started its operations in 2005. Komsomolskoye North (Severo-Komsomolskoye) (ELI) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs. We also...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gitr Antagonist in Autoimmune Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GITR Antagonist in Autoimmune Disorders Drug Details:The therapeutic candidate is under development for the treatment of...
-
Product Insights
New![]()
Net Present Value Model: AstraZeneca Plc’s Capivasertib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Autolus Therapeutics Plc’s Obecabtagene autoleucel
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Novo Nordisk AS’s NN-1845
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: BiomX Inc’s BX-004
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.